MEGA GENOMICS (06667) announced its financial results for 2025, achieving an operating revenue of approximately 247 million yuan, representing a year-on-year increase of 50.5%. Net profit was 27.021 million yuan, a decrease of 40% compared to the previous year. The adjusted net profit was 41.974 million yuan, up 6.9% year-on-year.

The growth in revenue was primarily attributed to the Group's continuous expansion of product categories, optimization of its product portfolio, and enhancement of its overall business structure. Multiple initiatives worked in synergy to effectively drive steady growth in total revenue. The decrease in net profit was mainly due to the combined impact of certain one-off expenses and financial asset impairments. During the reporting period, the company recorded a financial asset impairment of 9.5 million yuan, compared to a net reversal of 7.3 million yuan in the same period last year. Additionally, the Group recognized one-off expenses related to resumption of trading amounting to 5.5 million yuan, alongside donations totaling 1.9 million yuan for the Hong Kong Tai Po fire and other public welfare projects.

Excluding the effects of the financial asset impairment changes and the one-off related expenses, the Group's adjusted net profit showed growth compared to the same period last year, indicating that the profitability of its core business remained robust and positive.